Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAP-1002 (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions; Therapeutic Use
Acronyms HOPE-2-OLE
Sponsors Capricor

Most Recent Events

14 Nov 2023 According to a Capricor Therapeutics media release, data from this trial were presented at the 28th International Annual Congress of the World Muscle Society (WMS).
24 Oct 2023 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
07 Aug 2023 According to a Capricor Therapeutics media release, company plans to submit data from this study at a medical meeting in the fourth quarter of 2023

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight